162 related articles for article (PubMed ID: 37195572)
1. Soluble urokinase plasminogen activator receptor is associated with cardiovascular calcification in peritoneal dialysis patients.
Guan J; Gong S; He Q; Wang X; Shen S; Wu X; Shan J; Gong T; Yang Y; Xie H
Int Urol Nephrol; 2024 Jan; 56(1):191-198. PubMed ID: 37195572
[TBL] [Abstract][Full Text] [Related]
2. Soluble Urokinase Plasminogen Activator Receptor is Associated with Coronary Artery Calcification and Cardiovascular Disease in Patients Undergoing Hemodialysis.
Wu W; Cui Y; Hu J; Liao R; Li S; Mo L; Xu L; Chen Y; Lian Z; Tian X; Li Z; Li R; Zhang L; Liang H; Ma J; Lin T; Feng Z; Dong W; Ke G; Ge P; Ye Z; Wang W; Zhang B; Shi W; Liang X; Liu S
Kidney Blood Press Res; 2018; 43(3):664-672. PubMed ID: 29734173
[TBL] [Abstract][Full Text] [Related]
3. Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects.
Sørensen MH; Gerke O; Eugen-Olsen J; Munkholm H; Lambrechtsen J; Sand NP; Mickley H; Rasmussen LM; Olsen MH; Diederichsen A
Atherosclerosis; 2014 Nov; 237(1):60-6. PubMed ID: 25222341
[TBL] [Abstract][Full Text] [Related]
4. Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High-Sensitivity C-Reactive Protein.
Hayek SS; Divers J; Raad M; Xu J; Bowden DW; Tracy M; Reiser J; Freedman BI
J Am Heart Assoc; 2018 May; 7(9):. PubMed ID: 29716888
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and risk factors for vascular calcification in Chinese patients receiving dialysis: baseline results from a prospective cohort study.
Liu ZH; Yu XQ; Yang JW; Jiang AL; Liu BC; Xing CY; Lou JZ; Wang M; Cheng H; Liu J; Fu JZ; Zhang AH; Zhang M; Zhou QL; Yu C; Wang R; Wang L; Chen YQ; Guan TJ; Peng A; Chen N; Hao CM; Cheng XY;
Curr Med Res Opin; 2018 Aug; 34(8):1491-1500. PubMed ID: 29672176
[TBL] [Abstract][Full Text] [Related]
6. Cardiac valve calcification as a predictor of cardiovascular outcomes in peritoneal dialysis patients: an inverse probability of treatment weighting analysis.
Guan J; Xie H; Wang H; Gong S; Wu X; Gong T; Shen S
Int Urol Nephrol; 2023 May; 55(5):1271-1278. PubMed ID: 36454448
[TBL] [Abstract][Full Text] [Related]
7. Soluble urokinase Plasminogen Activator Receptor (suPAR) mediates the effect of a lower education level on adverse outcomes in patients with coronary artery disease.
Füller D; Liu C; Ko YA; Alkhoder AA; Desai SR; Almuwaqqat Z; Patel SA; Ejaz K; Kauser T; Martini MA; Alvi Z; Mehta PK; Sperling LS; Quyyumi AA
Eur J Prev Cardiol; 2024 Mar; 31(5):521-528. PubMed ID: 37788634
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of suPAR and hs-CRP on cardiovascular disease.
Diederichsen MZ; Diederichsen SZ; Mickley H; Steffensen FH; Lambrechtsen J; Sand NPR; Christensen KL; Olsen MH; Diederichsen A; Grønhøj MH
Atherosclerosis; 2018 Apr; 271():245-251. PubMed ID: 29402404
[TBL] [Abstract][Full Text] [Related]
9. Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.
Samman Tahhan A; Hayek SS; Sandesara P; Hajjari J; Hammadah M; O'Neal WT; Kelli HM; Alkhoder A; Ghasemzadeh N; Ko YA; Aida H; Gafeer MM; Abdelhadi N; Mohammed KH; Patel K; Arya S; Reiser J; Vaccarino V; Sperling L; Quyyumi A
Atherosclerosis; 2017 Sep; 264():108-114. PubMed ID: 28728756
[TBL] [Abstract][Full Text] [Related]
10. Abdominal aortic calcification score predicts the occurrence of coronary artery disease in middle-aged peritoneal dialysis patients.
Chen HC; Chou CY; Lin HJ; Huang CC; Chang CT
Nephrology (Carlton); 2019 Mar; 24(3):336-340. PubMed ID: 29405547
[TBL] [Abstract][Full Text] [Related]
11. Soluble urokinase plasminogen activator receptor: from biomarker to active participant in atherosclerosis and cardiovascular disease.
Goodchild TT; Li Z; Lefer DJ
J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36519539
[TBL] [Abstract][Full Text] [Related]
12. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
Mekonnen G; Corban MT; Hung OY; Eshtehardi P; Eapen DJ; Al-Kassem H; Rasoul-Arzrumly E; Gogas BD; McDaniel MC; Pielak T; Thorball CW; Sperling L; Quyyumi AA; Samady H
Atherosclerosis; 2015 Mar; 239(1):55-60. PubMed ID: 25574858
[TBL] [Abstract][Full Text] [Related]
13. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.
Persson M; Engström G; Björkbacka H; Hedblad B
Atherosclerosis; 2012 Feb; 220(2):502-5. PubMed ID: 22119508
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of some risk factors of coronary artery calcification in peritoneal dialysis patients].
Janicka L; Czekajska-Chehab E; Duma D; Grzebalska AM; Mierzicki P; Orłowska-Kowalik G; Solski J; Drop A; Ksiazek A
Pol Arch Med Wewn; 2006 Apr; 115(4):314-20. PubMed ID: 17078489
[TBL] [Abstract][Full Text] [Related]
15. Independent impact of periodontitis and cardiovascular disease on elevated soluble urokinase-type plasminogen activator receptor (suPAR) levels.
Isola G; Polizzi A; Alibrandi A; Williams RC; Leonardi R
J Periodontol; 2021 Jun; 92(6):896-906. PubMed ID: 33091149
[TBL] [Abstract][Full Text] [Related]
16. Value of soluble Urokinase plasminogen activator receptor over age as a biomarker of impaired myocardial relaxation.
Koh AS; Velmurugan B; Gao F; Tan RS; Wong JI; Teo LLY; Keng BMH; Chua SJM; Yuan JM; Koh WP; Cheung C
BMC Geriatr; 2017 Nov; 17(1):275. PubMed ID: 29179674
[TBL] [Abstract][Full Text] [Related]
17. Circulating Soluble Urokinase Plasminogen Activator Receptor as a Predictive Indicator for COVID-19-Associated Acute Kidney Injury and Mortality: Clinical and Bioinformatics Analysis.
Abdellatif HAA; Sultan BO; Nassar HM; Gomaa MEE; Sakr MG; Riad E; Al-Harbi AI; Abdulhakim JA; Fawzy MS; Abd El-Fadeal NM
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108340
[TBL] [Abstract][Full Text] [Related]
18. Clinical and prognostic usefulness of soluble urokinase plasminogen activator receptor in hemodialysis patients.
Wlazeł RN; Szadkowska I; Bartnicki P; Rośniak-Bąk K; Rysz J
Int Urol Nephrol; 2018 Feb; 50(2):339-345. PubMed ID: 29313168
[TBL] [Abstract][Full Text] [Related]
19. Valvular calcification and left ventricular modifying in peritoneal dialysis patients.
Rebić D; Rašić S; Hamzić-Mehmedbašić A; Džemidžić J; Kurtalić E
Ren Fail; 2015; 37(8):1316-22. PubMed ID: 26287980
[TBL] [Abstract][Full Text] [Related]
20. Relationship between cardiac calcification and left ventricular hypertrophy in patients with chronic kidney disease at hemodialysis initiation.
Kitamura K; Fujii H; Nakai K; Kono K; Goto S; Nishii T; Kono A; Nishi S
Heart Vessels; 2017 Sep; 32(9):1109-1116. PubMed ID: 28324126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
